EIM
CRVS icon

Essex Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Essex Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,225
Closed -$649K – 347
2017
Q1 		$649K Buy
31,225
+9,933
+47% +$156K 0.1% 241
2016
Q4 		$304K Buy
+21,292
New +$324K 0.05% 293

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Essex Investment Management's CRVS Position: Q2 2017 in Review

Essex Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 31,225 shares — an estimated $649K sold.

Essex Investment Management first reported a position in CRVS in Q4 2016 and held it in 2 quarters. The position peaked at $649K in Q1 2017. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Essex Investment Management reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Essex Investment Management sold 31,225 Corvus Pharmaceuticals shares in Q2 2017, an estimated $649K.
  • Essex Investment Management first reported a position in Corvus Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Essex Investment Management's Corvus Pharmaceuticals position peaked at $649K in Q1 2017.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Essex Investment Management's 13F filing for Q2 2017, filed 28 Jul 2017.